BOTOX Chronic Migraine Treatment: 2026 Clinical Guide

FDA-Approved BOTOX Treatment for Chronic Migraine: Clinical Guidelines, Patient Selection, and Integrated Care

For someone living with migraine, the difference between eight headache days and eighteen headache days a month can change nearly every part of life. It can also change which preventive treatments are medically appropriate.

Consider two fictional patients. Maria experiences headaches on 18 days each month, with migraine symptoms on at least 10 of those days. Her attacks have continued for more than six months, often last five or six hours, and interfere with work, sleep, driving, and family responsibilities. She has already tried preventive medication but struggled with side effects.

Daniel has a different pattern. He experiences eight to ten headache days each month. Seven have classic migraine features, and several are disabling enough that he misses work. He clearly deserves preventive migraine care, but his headache frequency does not meet the definition of chronic migraine.

Both patients have migraine. Both need treatment. Yet only Maria’s pattern may fit the clinical framework associated with FDA-approved BOTOX® treatment for chronic migraine after an appropriate medical evaluation.

That distinction matters more than ever because the updated 2026 American Academy of Neurology and American Headache Society migraine-prevention guideline recognizes many effective preventive options. The goal is no longer to force every patient through the same medication sequence. Instead, clinicians are encouraged to consider effectiveness, tolerability, medical conditions, medication interactions, reproductive considerations, cost, route of treatment, and patient preferences when developing a preventive plan (Potrebic et al., 2026).

What Is FDA-Approved BOTOX for Chronic Migraine?

BOTOX is the brand name for onabotulinumtoxinA. Although many people associate BOTOX with cosmetic treatment, the medication also has several medical indications.

For chronic migraine, BOTOX is FDA-approved for the prophylaxis, or prevention, of headaches in adults with chronic migraine. Current prescribing information describes the indication as adults experiencing at least 15 headache days per month, with headaches lasting four hours a day or longer. The labeling specifically notes that safety and effectiveness have not been established for preventing episodic migraine in patients with 14 or fewer headache days per month (AbbVie, 2026).

This is preventive treatment. BOTOX is not designed as an emergency injection that immediately stops an active migraine attack.

That difference matters when patients ask, “Can I get BOTOX because I have migraines?” Having migraine alone does not automatically establish the FDA-approved chronic migraine indication.

Chronic Migraine Is More Than Simply “Frequent Headaches”

Modern clinical diagnosis is typically informed by the International Classification of Headache Disorders, Third Edition, or ICHD-3.

Under ICHD-3 criteria, chronic migraine involves headaches on 15 or more days per month for more than three months, with migraine features on at least eight days per month, in a person with the appropriate previous migraine history. The symptoms must also not be better explained by another headache disorder (International Headache Society, 2018).

This distinction helps explain why a detailed headache diary can be so valuable.

A clinician may need to determine how many days involve any headache, how many meet migraine criteria, how long attacks last, whether acute medication changes symptoms, and whether another condition could better explain the headaches.

Patients may also underestimate their headache frequency. Someone may report “eight migraines a month” while forgetting an additional ten days of milder pressure or residual headache. Conversely, someone experiencing severe migraines every weekend may have tremendous disability but still fall below the chronic migraine threshold.

Both patients require care. They simply may require different preventive strategies.

The 2026 AAN/AHS Guideline Changes the Prevention Conversation

In August 2026, the American Academy of Neurology and American Headache Society published an updated joint practice guideline for pharmacologic migraine prevention in adults.

One of its most important messages is that preventive therapy should not be reserved only for people who have progressed to chronic migraine. Clinicians should offer preventive treatment when patients experience at least four migraine days per month, at least four moderate-to-severe headache days per month, or substantial migraine-related disability (Potrebic et al., 2026).

That recommendation does not expand the FDA BOTOX indication to episodic migraine.

Instead, it means Daniel, our fictional patient with eight to ten monthly headache days, should still have a serious preventive-treatment discussion even though BOTOX would not fit the labeled chronic migraine indication.

The guideline identifies onabotulinumtoxinA among the preventive treatments supported by high- or moderate-confidence evidence for chronic migraine. The accompanying systematic review found high-confidence evidence that onabotulinumtoxinA reduces headache frequency in chronic migraine (Pringsheim et al., 2026).

The guideline also emphasizes patient autonomy. Clinicians should not select a preventive medication from a checklist alone. Clinicians should discuss benefits, risks, side effects, comorbidities, contraindications, affordability, treatment route, and what matters most to the individual patient.

What Happens During the PREEMPT Injection Protocol?

The landmark Phase III Research Evaluating Migraine Prophylaxis Therapy program—better known as PREEMPT—established the evidence base for onabotulinumtoxinA in chronic migraine.

Current U.S. prescribing information recommends 155 units administered intramuscularly across 31 injection sites involving seven head and neck muscle regions, with repeat treatment every 12 weeks (AbbVie, 2026).

The labeled distribution includes:

• Frontalis: 20 units across four sites; corrugator: 10 units across two sites; procerus: 5 units at one site; occipitalis: 30 units across six sites; temporalis: 40 units across eight sites; trapezius: 30 units across six sites; and cervical paraspinal muscles: 20 units across four sites, for a total of 155 units at 31 sites.

The original PREEMPT clinical trials evaluated doses ranging from 155 to 195 units every 12 weeks. That research protocol should be distinguished from the current U.S. labeling, which specifies a recommended 155-unit dose (Dodick et al., 2010).

This is another reason migraine BOTOX should not be confused with cosmetic injections. The indication, anatomy, dosing strategy, treatment goals, clinical documentation, and follow-up are different.

What Did the PREEMPT Trials Show

The pooled PREEMPT analysis included 1,384 adults with chronic migraine.

By week 24, patients receiving onabotulinumtoxinA had an average reduction of approximately 8.4 headache days from baseline, compared with 6.6 days among patients receiving placebo. The between-group difference was statistically significant. Improvements were also found across several measures of migraine burden, disability, and quality of life (Dodick et al., 2010).

These results should be interpreted realistically.

BOTOX does not guarantee migraines will disappear. A person can respond meaningfully without becoming completely headache-free. Fewer headache days, reduced severity, improved ability to work, less sleep disruption, and fewer days lost to migraine can all matter clinically.

Longer-term PREEMPT analyses have also shown improvements in quality-of-life measures during repeated treatment (Aurora et al., 2011; Lipton et al., 2016).

Importantly, the 2026 AAN/AHS guideline recommends allowing 24 weeks at the recommended dose before judging the effectiveness of onabotulinumtoxinA for migraine prevention. That generally means clinicians should not dismiss treatment response simply because a patient did not experience dramatic improvement after the first cycle (Potrebic et al., 2026).

Patient Selection Requires More Than Counting Headache Days

Maria’s 18 headache days and 10 migraine days may make her a possible chronic migraine candidate, but frequency alone is not enough.

A responsible evaluation may examine headache history, attack duration and characteristics, aura symptoms, nausea, light or sound sensitivity, medication use, prior preventive therapies, acute-treatment frequency, pregnancy considerations, neurological symptoms, blood pressure, sleep, musculoskeletal complaints, previous head or neck trauma, and relevant medical conditions.

The clinician must also consider whether another diagnosis is present.

Cervicogenic headache, medication-overuse headache, occipital neuralgia, tension-type headache, sinus-related symptoms, post-traumatic headache, temporomandibular disorders, and secondary headache disorders can overlap with symptoms that patients describe as “migraine.”

A new severe headache, rapidly changing headache pattern, neurological deficit, fever, significant trauma, altered consciousness, or other warning sign may require additional investigation rather than automatically proceeding to preventive injections.

This is where accurate diagnosis becomes an act of both beneficence and non-maleficence: select treatments likely to benefit the patient while avoiding unnecessary or inappropriate procedures.

Medication Reconciliation Can Change the Treatment Plan

Medication reconciliation is especially important before preventive migraine therapy.

Patients may take triptans, gepants, NSAIDs, combination analgesics, antidepressants, anticonvulsants, blood-pressure medications, muscle relaxants, supplements, hormonal medications, or other treatments from several clinicians. A complete list helps identify medication overuse, potential interactions, contraindications, and opportunities to simplify treatment.

For BOTOX specifically, prescribing information calls for caution with medications that interfere with neuromuscular transmission, including aminoglycoside antibiotics and certain muscle relaxants. The patient’s previous exposure to other botulinum toxin products is also relevant because BOTOX potency units are product-specific and are not interchangeable with those of other botulinum toxin preparations (AbbVie, 2026).

The 2026 guideline also specifically supports preventive treatment for patients with medication overuse or medication-overuse headache and identifies onabotulinumtoxinA as a treatment with efficacy evidence in these populations (Potrebic et al., 2026).

Safety, Contraindications, and Informed Consent

BOTOX should not be presented as risk-free simply because injections are performed in an outpatient setting.

Current prescribing information identifies two major contraindications relevant to chronic migraine injections: known hypersensitivity to a botulinum toxin product or formulation component and infection at the proposed injection site (AbbVie, 2026).

Patients with neuromuscular diseases or neuromuscular-junction disorders may have an increased risk of clinically significant weakness and require careful assessment. Pre-existing swallowing or breathing problems also deserve special attention.

The prescribing information includes a boxed warning about the potential for distant spread of the toxin’s effects. Symptoms can include generalized weakness, double vision, eyelid drooping, speech or swallowing difficulty, and breathing problems. Patients should seek immediate medical care if significant swallowing, speech, or respiratory difficulties develop after treatment. The current label also notes that definitive serious distant-spread events have not been reported for chronic migraine when BOTOX is used at labeled doses.

In chronic migraine trials, commonly reported adverse events included neck pain, headache, eyelid ptosis, muscular weakness, musculoskeletal stiffness, injection-site pain, and several less common effects. Neck pain occurred in approximately 9% of treated patients compared with 3% of those receiving placebo in the trials summarized in the prescribing information.

Pregnancy requires individualized consideration. The 2026 AAN/AHS guideline notes that outcome data remain extremely limited and recommends balancing potential risks and benefits when onabotulinumtoxinA is considered necessary for chronic migraine during pregnancy (Potrebic et al., 2026).

Why Maria and Daniel May Need Different Preventive Strategies

Returning to our two patients demonstrates why personalized migraine care matters.

Maria has 18 monthly headache days, at least 10 migraine days, prolonged attacks, and significant disability. Her history potentially fits chronic migraine criteria. After a complete examination, medication review, consideration of contraindications, and confirmation that another disorder does not better explain her symptoms, onabotulinumtoxinA could be among the evidence-supported preventive options discussed with her.

Daniel has a disabling migraine but fewer than 15 headache days each month. He still meets the 2026 guideline threshold for discussing prevention, but FDA-approved BOTOX for chronic migraine would not fit his current headache frequency.

His clinician might instead discuss other evidence-supported preventive therapies appropriate for episodic migraine while considering his health history, previous treatment, side-effect concerns, cost, reproductive considerations, and preferences.

The lesson is simple: the best preventive strategy is not determined by the word “migraine” alone.

Integrated Migraine Evaluation at Injury Medical Chiropractic and Functional Medicine Clinic

Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, brings an unusual combination of chiropractic and advanced-practice nursing credentials to multidisciplinary evaluation. The clinic website identifies him as both a licensed chiropractor and board-certified family nurse practitioner and lists Texas APRN/FNP license number 1191402 and NPI 1205907805. Dr. Maria Guadalupe Cardenas, MD, is identified as the clinic’s medical director, clinical director, collaborative physician, and board-certified internal medicine physician, with Texas license J2933 and NPI 1164426748.

That structure may be useful when migraine exists alongside cervical pain, soft-tissue injury, sleep disruption, medication questions, metabolic disease, hypertension, or other medical issues. Dr. Jimenez’s musculoskeletal and soft-tissue perspective can help evaluate physical contributors, while his APRN/FNP-BC role supports medical history review and medication reconciliation within scope. Dr. Cardenas can provide internal medicine direction and coordination for more complex medical concerns.

The clinic’s current website also explicitly lists Botox and migraine Botox among its available services, so discussing migraine BOTOX as an advertised clinic service is supported by the clinic’s present public information.

Do not claim this is the only El Paso clinic providing chronic-migraine BOTOX. Current public information shows that other El Paso medical practices also advertise BOTOX for migraine. A stronger, more defensible differentiator is the clinic’s integrated model combining chiropractic physical medicine, family nurse practitioner evaluation, internal-medicine oversight, rehabilitation, and functional-health perspectives.

This model also supports three important ethical principles. Beneficence means selecting care expected to improve function and reduce migraine burden. Non-maleficence means recognizing contraindications, avoiding unnecessary procedures, and carefully weighing medication and injection risks. Autonomy means educating patients so they can participate meaningfully in decisions and continue coordinating care with their neurologist, primary-care physician, gynecologist, or other established healthcare professionals.

A Migraine Treatment Plan Should Fit the Patient

The 2026 migraine guideline reinforces something patients have long experienced: two people carrying the same migraine diagnosis may need very different treatment plans.

One patient may qualify for FDA-approved BOTOX because chronic migraine occurs on at least 15 headache days each month. Another may have fewer attacks but enough disability to benefit from a different preventive medication. A third may have a migraine complicated by medication overuse. Someone else may need evaluation of sleep, neck trauma, pregnancy, cardiovascular disease, neurological symptoms, or another condition before treatment is selected.

Effective migraine care therefore begins before the injection.

It begins with listening, accurately counting headache and migraine days, reviewing medications, identifying warning signs, evaluating the full medical picture, and helping the patient understand the available choices.

For appropriate adults with chronic migraine, onabotulinumtoxinA is no longer an experimental or cosmetic concept. It is an FDA-approved preventive therapy supported by the PREEMPT trials and recognized as an evidence-based chronic migraine option in the updated 2026 AAN/AHS guideline.

The question is not simply, “Does BOTOX work for migraines?”

The better question is, “Is this the right preventive strategy for this  patient?”

Migraine Pain Treatment El Paso, TX Chiropractor

Suggested DrAlexJimenez.com Internal Links

Within the published article, appropriate internal links include the clinic’s migraine and headache educational content, provider credentials, multidisciplinary care information, and appointment resources:

Headaches and Treatment — useful when discussing headache diaries, migraine patterns, and conservative evaluation. Headaches and Treatment

Doctor Diagnosis for Headaches and Migraines — appropriate around the differential-diagnosis and patient-selection sections. Diagnosis for Headaches and Migraines

Staff/Provider Credentials—appropriate when introducing Dr. Jimenez and Dr. Cardenas. Injury Medical Clinic Staff

Multidisciplinary Integrative Medicine—appropriate for the integrated-care section. Multidisciplinary Integrative Medicine

---

References

AbbVie Inc. (2026). BOTOX (onabotulinumtoxinA) prescribing information [Revised February 2026]. U.S. National Library of Medicine, DailyMed. BOTOX Prescribing Information

Aurora, S. K., Winner, P., Freeman, M. C., Spierings, E. L., Heiring, J. O., DeGryse, R. E., VanDenburgh, A. M., Nolan, M. E., & Turkel, C. C. (2011). OnabotulinumtoxinA for treatment of chronic migraine: Pooled analyses of the 56-week PREEMPT clinical program. Headache, 51(9), 1358–1373. PREEMPT 56-Week Pooled Analysis

Dodick, D. W., Turkel, C. C., DeGryse, R. E., Aurora, S. K., Silberstein, S. D., Lipton, R. B., Diener, H.-C., & Brin, M. F. (2010). OnabotulinumtoxinA for treatment of chronic migraine: Pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache, 50(6), 921–936. PREEMPT Pooled Results

International Headache Society. (2018). Chronic migraine. In International Classification of Headache Disorders (3rd ed.). ICHD-3 Chronic Migraine Criteria

Potrebic, S., Tanveer, S., Becker, W. J., Burch, R., Cooke, L. J., Fenton, T., Fletcher, J. J., Gordon Perue, G. L., Hershey, A. D., Jackson, J. L., Kessel, S., Loder, E. W., Minen, M. T., Oskoui, M., Ramanan, V. K., Murren, M., Schwedt, T. J., Silberstein, S. D., Smith, D. B., … Pringsheim, T. (2026). Pharmacologic treatment for migraine prevention in adults practice guideline recommendations: Report of the AAN Guidelines Subcommittee and the American Headache Society. Neurology, 107(7), e214881. 2026 AAN/AHS Migraine Prevention Guideline

Pringsheim, T., Smith, D. B., Tanveer, S., et al. (2026). Systematic review of pharmacologic treatment for migraine prevention in adults: Report of the AAN Guidelines Subcommittee and the American Headache Society. Neurology, 107(7), e218112. 2026 AAN/AHS Systematic Review

Medical disclaimer: This educational material does not establish a diagnosis or individual treatment recommendation. Chronic migraine and eligibility for preventive therapy should be evaluated by an appropriately licensed healthcare professional. BOTOX is a prescription medication with contraindications, warnings, and potential adverse effects.